Pulmonary Hypertension Association

PULMONARY HYPERTENSION ASSOCIATION NEWS

Positive Data from INSPIRE Trial Released

New data from “INSPIRE: A Phase 3 Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of LIQ861 in PAH” was presented last week during

Openings Still Available for Webinar Participation in FDA Meeting to Gather Input on Living With a Rare Disease

The U.S. Food and Drug Administration (FDA) reports that the in-person registration for their April 29 public meeting “Patient Perspectives on the Impact of Rare

PHA’s Community Helps Highlight Importance of Organ Donation

National Donate Life Month continues to celebrate the capacity we all possess to give life and hope by registering to become an organ donor. Every

Support the Online PH Community — Volunteer to Moderate a PHA Facebook Group

The Pulmonary Hypertension Association (PHA) currently hosts five specific Facebook groups for people living with PH. These groups provide members with a supportive space to

PHA Helps Highlight the Importance of Organ Donation During National Donate Life Month

April is National Donate Life Month and all month long the Pulmonary Hypertension Association (PHA) is bringing awareness to transplant recipients, individuals still on the

PHA’s PH Care Centers (PHCC) Program Accredits Five New Centers

The Pulmonary Hypertension Association’s (PHA’s) PH Care Centers (PHCC) Program recently accredited five new centers in support of its commitment to promoting quality care practices

Generic Treprostinil Injection Launched for Intravenous Use

Generic treprostinil, the pulmonary arterial hypertension--targeted therapy currently sold as Remodulin®, is now available for individuals using the medication delivered intravenously. Generic treprostinil injection is